A panel of federal judges has rejected an attempt by Bristol-Myers Squibb and Sanofi-Aventis to consolidate all Plavix lawsuits pending in various federal district courts as part of an MDL, or multi-district litigation, where they would have been managed in a manner similar to a Plavix class action lawsuit during… Read more.
The FDA has announced a “black box” Plavix warning, indicating that the anti-clotting medication may be ineffective in some patients with a genetic variation. This could cause an individual at risk for a heart attack, stroke, angina or cardiovascular death to suffer a serious and potentially life-threatening injury.
New research indicates that heart patients who are given Plavix after receiving a stent or having a heart attack, could have an increased risk of death or a new heart attack within 90 days after they stop taking the drug. The information new could alter the way doctors prescribe Plavix… Read more.
Drug coated heart stents have been linked to an increased risk of serious and potentially fatal blood clots which could develop years after the stent is implanted. However, there are many individuals who have not experienced a blood clot, heart attack or reclogging of the artery, yet now must remain… Read more.
In recent television advertisements, Plavix side effects are minimized while viewers are led to believe that they must take the drug to avoid a potentially fatal blood clot. Individuals who fear a heart attack are encouraged to seek out the medication from their doctor, even if they do not fit… Read more.
Following the meeting of an FDA panel of experts last week, it does not appear that there will be a drug coated stent recall or removal from the market. However, medical experts have still indicated that there are serious safety concerns associated with drug eluting stents. Most patients currently receiving… Read more.
An FDA panel of experts is expected to meet this week to review the drug eluting stent problems, which have generated a lot of concern in the medical community. They will evaluate the drug coated stent blood clot risk, and make recommendations to the FDA about what should be done… Read more.
One of the less common, but certainly very serious, Plavix side effects is the increased risk of TTP (thrombotic thrombocytopenic purpura). TTP is a rare blood condition which can be fatal. The manufacturers of Plavix did not adequately and fully warn of this potential side effect which could occur after… Read more.
Recently serious questions have been raised about the safety of medicated stents, which are widely used during angioplasty proceedures following heart attacks. Cardiologists have expressed concerns about medicated stent side effects which may increase risk of heart attacks and blood clots for years after the proceedure.
Plavix was approved in April 1997 after a rare priority regulatory review by the FDA. The expedited review was requested so that the medication could be brought to the market very quickly. When FDA advisory panel recommended that the agency approve the drug, reservations were expressed by some panel members… Read more.
